Bayer Rises After Panel Backs Blood Thinner for Heart Use
This article is for subscribers only.
Bayer AG rose the most in 10 months in Frankfurt trading after its blood thinner Xarelto won an advisory panel’s support as a treatment to prevent stroke in patients with the most common abnormal heart rhythm.
The drug, known chemically as rivaroxaban, was recommended for atrial fibrillation patients in a 9-2 vote with one abstention by advisers to the Food and Drug Administration meeting yesterday in Adelphi, Maryland. The agency is scheduled to decide whether to approve Xarelto by Nov. 5 and isn’t required to follow the recommendation.